EICHORCondition: Glioma · BRAF V600E · Pleomorphic Xantho-Astrocytoma · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | — |
| Massachusettes General Hospital | Boston, Massachusetts, United States | — |
| Wake Forest Baptist Medical Center | Winston-Salem, North Carolina, United States | — |
| Penn State Hershey Medical Center | Hershey, Pennsylvania, United States | — |
| University of Pennsylvania Abramson Cancer Center | Philadelphia, Pennsylvania, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03593993